We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Experts Spar Over FDA Meeting To Re-Evaluate GSK’s Avandia
Experts Spar Over FDA Meeting To Re-Evaluate GSK’s Avandia
May 23, 2013
The FDA’s plans to reassess the heart risks of GlaxoSmithKline’s (GSK) diabetes drug Avandia have generated conflicting industry-expert comments about the meeting’s purpose.